OXNARD, CALIFORNIA – CURE Pharmaceutical will be collaborating with Canopy Growth Corp. to produce low-dose cannabidiol (CBD) oral thin film (OTF) to help administer CBD in the right dosages. This collaboration will leverage CURE’s patented technology, CUREfilm and will also allow the two companies to distribute CBD globally.
“This collaboration builds on our licensing agreement with canopy and accelerates product commercialization,” according to Rob Davidson, the Chief Executive Officer of CURE Pharmaceutical. “We will leverage our recent patented development in cannabis-based drug delivery, to formulate an oral thin film product for optimal efficacy and dosing frequency.”
CURE Pharmaceutical is a registered company under the U.S. Drug Enforcement Agency (DEA). It makes use of its patented CUREfilm technology in developing and manufacturing cannabis-derived and synthetic CBD-based products. It is also a known company that is federally-compliant on the regulations of its industry even during collaborations with other CBD growers and manufacturers.
The Condor CBD Gummies have been the talk of the hemp-derived cannabidiol edibles as of…
Delta 8 THC is a naturally occurring cannabinoid commonly produced from hemp-derived CBD. It’s relatively…
With more people turning towards natural remedies in recent years, mushroom supplements have taken the…
The Circle Labs CBD Balm is extracted using a cold-infusion process and is an effective…
If anyone is looking for a CBD supplement that is packed with all the necessary…
If anyone has been searching the internet for all the benefits of CBD and where…